Crispr Therapeutics is a biotechnology company focused on developing gene-editing therapies.
The third name in the short-interest basket, chosen for replicating the same technical pattern: high short interest, consolidation around the 200-day MA with the 9/21 EMAs pointing up and a golden cross imminent.